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 Abstract
Objectives: O-GlcNAcylation is an abundant modification of cellular proteins which consist of single 
N-acetylglucosamine residues attached by O-linkage to serine or threonine residues. Abnormal O-GlcNAcylation 
seems to be a feature of malignant cancer cells. The aim of the present study was to determine the relationship 
between the expression of genes encoding O-GlcNAc cycling enzymes (OGT and MGEA5) and clinicopathological 
parameters of endometrial carcinomas.
Materials and methods: The mRNA expression levels of O-GlcNAc cycling enzymes in series of 76 samples of 
endometrial carcinoma were studied by real time RT-PCR method.
Results: The OGT and MGEA5 mRNA expression was significantly higher in tumors of higher histological grade 
than in well-differentiated tumors. Statistically significant association was found between OGT and MGEA5 mRNA 
expression and depth of myometrial invasion. Both OGT and MGEA5 expression profiles showed no significant 
association with the clinical stage of endometrial cancer.
Conclusion: O-GlcNAcylation may be an important regulatory modification involved in endometrial cancer 
pathogenesis but the actual significance of this modification for endometrial cancer progression needs to be 
investigated further.
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Introduction
O-GlcNAcylation	 is	 an	 abundant	 post-translational	
modification	 of	 nuclear	 and	 cytoplasmic	 proteins.	 O-GlcNAc	
transferase	 (OGT)	 catalyses	 covalent	 attachment	 of	 β-D-N-
acetylglucosamine	(GlcNAc)	sugars	to	serine	or	threonine	residues	
and	O-GlcNAcase	 (OGA)	catalyses	 the	 removal	of	O-GlcNAc	
residues.	OGT	is	encoded	by	a	single	gene	on	the	X	chromosome.	
The	cloned	sequence	of	O-GlcNAcase	was	found	to	be	identical	
to	that	of	MGEA5	(meningioma-expressed	antigen	5)	which	was	
identified	genetically	in	human	meningiomas.	MGEA5	localizes	
to	chromosome	10q24.1-q23.4	region	[1,	2].
There	 is	 growing	 evidence	 that	 O-GlcNAcylation	 plays	
a	 role	 in	 cancer-relevant	 processes,	 such	 as	 cell	 signaling,	
transcription,	 cell	 division,	 metabolism	 and	 cytoskeletal	
regulation	 [3].	 Several	malignancies	 have	 been	 shown	 to	 have	
abnormal	O-GlcNAcylation	level	compared	to	normal	tissues	[4-
8].	Elevated	OGT	mRNA	expression	was	found	in	breast	cancer	
cell	 lines	 and	 breast	 invasive	 ductal	 carcinoma	 compared	with	
normal	breast	cells	and	normal	breast	 tissue	 [4,	9].	 It	has	been	
shown	that	poorly	differentiated	breast	tumors	(grade	II	and	III)	
have	higher	OGT	expression	than	grade	I	tumors	and	lymph	node	
metastasis	 is	 significantly	 associated	 with	 decreased	 MGEA5 
mRNA	 expression	 [9].	 It	 is	 suggested	 that	 O-GlcNAcylation	
influences	 the	 malignant	 properties	 of	 breast	 cancer	 cells	 and	
promotes	 metastasis	 [5].	 Elevated	 O-GlcNAcylation	 in	 colon	
and	lung	cancers	is	correlated	with	increased	expression	of	OGT	
[6].	 The	 intracellular	 O-GlcNAcylation	 has	 been	 found	 to	 be	
associated	with	the	pathogenesis	of	chronic	lymphatic	leukemia	
–CLL	[7]	and	this	modification	plays	a	role	in	tumor	recurrence	
of	hepatocellular	carcinoma	following	liver	transplantation	[8].
Endometrial	cancer	is	the	most	common	malignant	tumor	of	
the	female	genital	tract.	In	the	endometrium	different	subtypes	of	
cancer	can	develop.	Endometrioid	endometrial	carcinoma	(EEC)	
or	Type	1	cancer	is	the	most	prevalent	subtype	and	accounts	for	
over	70%	of	cases.	EECs	are	estrogen-dependent	and	often	develop	
in	 the	background	of	atypical	complex	hyperplasia.	EECs	 tend	
to	present	as	low	grade,	early	stage	tumors	with	good	outcomes	
[10-12].	 However,	 a	 subset	 of	 patients	 have	 a	 biologically	
aggressive	 disease	 characterized	 by	 lymphovascular	 invasion,	
high	 histological	 grade,	 and	 myometrial	 invasion.	 Patients	
with	 these	characteristics	are	at	an	 increased	risk	of	 recurrence	
following	 hysterectomy.	 For	 early-stage	 disease,	 surgery	 alone	
or	 in	 combination	with	 local	 therapy	 is	generally	 curative.	For	
patients	with	 stage	 III	or	 stage	 IV	of	 the	disease	and	 for	 those	
with	 recurrent	 endometrial	 cancer,	 the	prognosis	 remains	poor.	
The	identification	of	differentially	expressed	genes	between	late	
vs.	 early	 stage	 endometrioid	 endometrial	 carcinoma	 might	 be	
important	for	predicting	tumor	progression	and	tumor	outcome.	
The	 new	 markers	 could	 help	 to	 decide	 the	 need	 for	 adjuvant	
treatment	and	to	identify	new	treatment	strategies.
In	 this	 study	 the	 authors	 analyzed	 the	 mRNA	 expression	
of	 genes	 encoding	 O-GlcNAc	 transferase	 and	 O-GlcNAcase	
(OGT and	MGEA5,	respectively)	in	endometrial	cancers	and	the	
relationship	 between	 their	 expression	 and	 clinicopathological	
parameters.
Materials and Methods
The	study	included	76	patients	with	endometrial	carcinoma	
who	had	undergone	surgery	at	the	Department	of	Gynecological	
Oncology	Copernicus	Memorial	Hospital,	Łódź,	Poland.	
All	 studied	 endometrial	 carcinoma	 specimens	 were	
hysterectomy	specimens.	Information	regarding	the	clinical	and	
pathological	characteristics	of	the	patient	populations	was	obtained	
from	the	medical	records.	The	endometrial	patients	characteristics	
are	presented	in	Table	I.	Endometrial	carcinomas	were	classified	
according	 to	 the	 criteria	 of	 the	 International	 Federation	 of	
Gynecology	 and	 Obstetrics	 (FIGO).	 Histological	 typing	 and	
grading	were	done	according	to	the	WHO	classification.
 Streszczenie
Cel pracy: O-GlcNAcylacja jest powszechną modyfikacją białek komórkowych polegającą na przyłączeniu wiązaniem 
O-glikozydowym pojedynczych reszt N-acetyloglukozoaminy do reszt seryny i treoniny. Zaburzenia O-GlcNAcylacji 
wydają się być istotną cechą związaną z agresywnością komórek nowotworowych. Celem prezentowanej pracy 
było określenie zależności pomiędzy ekspresją genów kodujących enzymy związane z O-GlcNAcylacją białek 
a kliniczno-patologicznymi parametrami raka błony śluzowej trzonu macicy.
Materiał i metody: Poziom ekspresji mRNA enzymów analizowano techniką real time RT-PCR w 76 preparatach 
raków błony śluzowej trzonu macicy.
Wyniki: Nowotwory o wyższym stopniu złośliwości histologicznej wykazywały wyższą ekspresję mRNA dla OGT 
i MGEA5 w porównaniu z rakami dobrze zróżnicowanymi. Stwierdzono również istotną statystycznie zależność 
pomiędzy ekspresją badanych genów a głębokością naciekania mięśniówki macicy. Nie stwierdzono natomiast 
zależności pomiędzy ekspresją mRNA OGT i MGEA5 a stopniem klinicznego zaawansowania nowotworu.
Wniosek: Wydaje się, że  O-GlcNAcylacja może być ważną regulatorową modyfikacją włączoną w patogenezę 
raka błony śluzowej trzonu macicy ale dokładne określenie jej roli w progresji tego nowotworu wymaga dalszych 
badań.
 Słowa kluczowe: O-GlcNAcylacja / OGT / MGEA5 / 
     / rak błony śluzowej trzonu macicy /   
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RNA extraction and cDNA synthesis
Total	RNA	was	isolated	using	Trizol® Reagent	(Sigma	Aldrich,	
USA)	 according	 to	 manufacturer’s	 protocol	 and	 quantified	
spectrophotometrically.	 First-strand	 cDNAs	 were	 obtained	 by	
reverse	transcription	of	1	µg	of	total	RNA	using	RevertAidTM	First	
strand	cDNA	synthesis	kit	 (Fermentas	 International,	Lithuania)	
following	the	manufacturer’s	protocol.
Quantitative real-time PCR
Real-time	 gene	 expression	 analysis	 of	 target	 genes	 (OGT 
and MGEA5)	was	 performed	 using	TaqMan® Gene	Expression	
Assays	(Applied	Biosystems,	USA)	according	to	manufacturer’s	
instructions.	The	GAPDH	gene	was	used	as	internal	control.	The	
assay	 numbers	 for	 these	 genes	 were	 as	 follows:	 Hs00201970,	
Hs00269228	and	Hs99999905.
Each	PCR	 reaction	was	performed	 in	a	10	µl	volume	 that	
included	5	µl	of	2x	TaqMan	Universal	PCR	MasterMix	(Applied	
Biosystems,	USA),	4.5	µl	of	water	diluted	cDNA	template	(50	ng)	
and	0.5	µl	of	TaqMan® Gene	Expression	Assay	consisted	of	a	pair	
of	unlabeled	PCR	primers	and	TaqMan	probe	with	a	FAMTM.	The	
RT-qPCR	 reaction	 was	 carried	 out	 using	 the	 Mastercycler	 ep	
realplex	(Eppendorf,	Germany)	under	the	following	conditions:	
denaturation	for	10	min	at	95ºC	followed	by	50	cycles	of	15	sec	
at	95ºC,	1	min	annealing	and	extension	at	60ºC.	
Relative	RNA	quantification	was	performed	using	 the	ΔCt	
method.	ΔCt	(Ctgene	–	CtGAPDH)	values	were	recalculated	into	
relative	copy	number	values	(number	of	OGT	or		MGEA5	mRNA	
copies	per	1000	copies	of	GAPDH	mRNA).
Statistical analysis
The	 statistical	 analyses	 were	 performed	 using	 the	
STATISTICA	 version	 9.0	 (StatSoft,	 Poland).	 Since	 levels	 of	
expression	in	endometrial	cancer	specimens	did	not	show	normal	
distribution	 (Kolmogorov-Smirnow	 test),	 the	 non-parametrical	
statistical	tests	(Mann-Whitney	U	test,	Kruskal-Wallis	test)	were	
applied.	The	chi	square	test	was	used	to	identify	the	relationship	
between	expression	of	OGT	or	MGEA5 and	clinicopathological	
parameters.	 A	 p-value	 <0.05	 was	 considered	 statistically	
significant.
Results 
OGT	 and	MGEA5	mRNA	 expression	was	 found	 in	 all	 76	
samples	of	the	studied	endometrial	cancers.	The	comparison	of	
the	q-RT-PCR	data	for	OGT and	MGEA5	in	EECs	with	different	
pathological	parameters	is	shown	in	Figure	1	and	2.	
The	OGT	and	MGEA5	mRNA	expression	was	significantly	
higher	 in	 tumors	of	grade	 II	 and	 III	 than	 in	well-differentiated	
tumors	 of	 grade	 I	 (Fig.1).	 The	 mean	 OGT	 and	 MGEA5 
expression	 levels	 in	grade	 II	were	7	 and	4.6	–fold	higher	 than	
in	grade	I,	 respectively.	Statistically	significant	association	was	
found	between	OGT and	MGEA5 mRNA	expression	and	depth	
of	 myometrial	 invasion.	 However,	 there	 were	 no	 significant	
differences	 (p>0.05)	 in	 OGT	 and	 MGEA5	 mRNA	 expression	
between	 tumors	 with	 different	 lymph	 node	 metastasis	 status	
(Figure1)	and	different	 stages	of	development	according	 to	 the	
FIGO	classification	(Figure	2).
Discussion
The	 role	of	O-GlcNAcylation	 in	 tumorigenesis	and	cancer	
progression	 has	 not	 been	 fully	 elucidated.	 However,	 many	
oncogenic	proteins	and	tumor	suppressor	proteins	are	regulated	
by	O-GlcNAcylation.	The	protooncogene	c-Myc	which	regulates	
transcription	 of	 genes	 involved	 in	 cell	 proliferation,	 apoptosis	
and	 metabolism	 is	 modified	 by	 O-GlcNAc	 at	 Thr58	 and	 this	
potentially	 stabilizes	 the	 protein	 [13].	 The	 important	 tumor	
suppressor	p53,	which	is	mutant	or	dysregulated	in	many	cancers	
including	some	endometrial	cancers,	bears	O-GlcNAc	at	Ser149.	
Increased	O-GlcNAcylation	of	p53	at	Ser149	results	in	decreased	
p53	 ubiquitination	 and	 stabilizes	 the	 p53	 protein	 [14].	 It	 was	
found	by	immunohistochemistry	that	high	expression	of	p53	was	
correlated	with	 an	 advanced	 stage,	 poor	 differentiation,	 lymph	
node	metastasis	 and	 deep	myometrial	 invasion	 of	 endometrial	
cancers	[15,	16].	It	is	possible	that	high	expression	of	p53	protein	
in	endometrial	cancer,	at	least	partially,	may	be	due	to	increased	
stability	of	this	protein	caused	by	O-GlcNAcylation.
Over	25%	of	the	O-GlcNAc	modified	proteins	are	involved	
in	 transcriptional	 regulation.	 O-GlcNAc	 modification	 of	
transcription	factors	is	important	in	regulation	of	gene	expression	
in	various	tissues	[17].	One	of	the	best	studied	O-GlcNAcylated	
transcription	 factors	 is	 Sp1	 which	 targets	 genes	 encoding	 for	
factors	 involved	 in	 cell	 cycle	 progression,	 both	 pro-	 and	 anti-
angiogenic	 factors	 involved	 in	 invasion	 and	 metastasis,	 pro-	
and	 anti-apoptotic	 factors	 involved	 in	genomic	 stability,	 proto-
oncogene	 and	 tumor	 suppressors	 stimulating	 cell	 proliferation	
and	oncogenesis	[18].	O-GlcNAcylation	of	Sp1	has	been	shown	
to	 regulate	 Sp1	 nuclear	 localization,	 transactivation	 capability,	
protein	 stability,	 and	 its	 interaction	 with	 other	 transcriptional	
regulators	 [19-22].	 Dynamic	 changes	 of	 O-GlcNAcylation	 of	
Sp1	as	well	as	many	other	transcription	factors	can	modulate	the	
malignant	properties	of	cancer	cells.	
Abnormal	 O-GlcNAcylation	 seems	 to	 be	 a	 feature	 of	
aggressive	cancer	cells.	It	was	shown	that	high	O-GlcNAcylation	
associated	 with	 high	 OGT	 expression	 might	 be	 a	 marker	 for	
progression	of	breast	cancer	[5,9].	Low	expression	of	OGA	was	
an	independent	prognostic	factor	for	predicting	tumor	recurrence	
of	hepatocellular	cancer	following	liver	transplantation	[8].
Median age (range) 62.5 (31 – 85)
FIGO stage
I 35
II 31
III 9
IV 1
Histological grade
GI 14
G II 49
G III 13
Depth of myometrial invasion
<1/2 38
>1/2 35
Lymph node metastasis
No 60
Yes 16
Table I. Clinical characteristics of the endometrial carcinoma. 
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The	aim	of	the	present	study	was	to	determine	whether	the	
expression	 of	 O-GlcNAc	 cycling	 enzymes	 is	 correlated	 with	
endometrial	cancer	malignancy.	Clinicopathological	studies	show	
that	poor	prognosis	is	related	among	others	to	histological	grade,	
deep	 myometrial	 invasion	 of	 malignant	 cells	 and	 lymph	 node	
metastasis.	The	results	have	shown	that	expression	of	both	genes	
is	increased	in	endometrial	cancers	of	higher	histological	grade	
what	might	suggest	 that	 less	differentiated	cancers	have	a	high	
rate	of	O-GlcNAc	cycling.	Although	increased	expression	of	both	
genes	was	observed,	 the	relative	expression	of	OGT	was	much	
higher	 than	MGEA5.	The	extent	of	myometrial	 invasion	 is	one	
of	important	prognostic	factors.	Expression	of	OGT	and	MGEA5 
was	 higher	 in	 case	 of	 cancers	with	 deep	myometrial	 invasion.	
However,	 there	 was	 no	 association	 between	 expression	 of	 the	
studied	genes	and	lymph	node	status	or	clinical	stage.	Although	
the	 results	of	our	preliminary	 studies	concerning	expression	of	
O-GlcNAc	cycling	enzymes	suggest	that	O-GlcNAcylation	may	
be	an	important	regulatory	modification	involved	in	endometrial	
cancer	pathogenesis,	the	actual	significance	of	this	modification	
for	endometrial	cancer	progression	needs	to	be	further	elucidated.	
Better	 insight	 into	 processes	 involved	 in	 endometrial	 cancer	
pathogenesis	 may	 lead	 to	 identification	 of	 novel	 biomarkers	
and	 targets	 for	 the	 development	 of	 diagnostic	 and	 therapeutic	
approaches	for	prevention	and	treatment	of	endometrial	cancer.	
Conclusions
The	 expression	 of	 genes	 encoding	 O-GlcNAc	 processing	
enzymes	 is	 significantly	 associated	 with	 aggressive	 features	
such	as	high-grade	and	deep	myometrial	invasion	which	suggest	
that	O-GlcNAcylation	may	 be	 involved	 in	 endometrial	 cancer	
progression.	 Additional	 investigations	 of	 O-GlcNAc	 cycling	
enzymes	 as	 a	biomarker	of	malignant	potential	 and	 as	 a	novel	
target	for	therapeutics	in	endometrial	carcinoma	are	necessary.
Figure 1.  OGT and MGEA5 mean mRNA expression level in endometrial carcinomas: a comparison between subgroups with different tumor grade, depth of myometrial 
invasion and lymph node metastasis status.  
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